Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature data generated utilizing the NeuroStar TMS (transcranial magnetic stimulation) System. In addition, NeuroStar will exhibit at booth #303.

“We are thrilled to present this meaningful evidence at the Clinical TMS Society Annual Meeting and engage with TMS providers and researchers about recent advancements in our field,” said Cory Anderson, Senior Vice President of Research & Development and Clinical Affairs. “Our extensive data and strong clinical presence establish NeuroStar as the leading TMS device, treating the highest number of patients and supporting providers in delivering exceptional patient care in clinical settings.”

The following data will be presented:

When to Hold and When to Fold: Early Prediction of Nonresponse to Transcranial Magnetic Stimulation in Major Depressive Disorder

  • Presenter: Dr. Harold Sackeim, Professor in Psychiatry and Radiology at Columbia University
  • Overview: In the poster and oral presentation, Dr. Sackeim will explain how early improvement reliably predicts potential responders to treatment; however, the absence of such improvement does not reliably forecast non-response.
  • Presentation Date: June 14th at 2:45 PM BST

The Impact of Treatment Gaps on Effectiveness of Transcranial Magnetic Stimulation in MDD

  • Presenter: Dr. Linda Carpenter, Professor of Psychiatry and Human Behavior at Brown University
  • Overview: Dr. Carpenter will present data regarding the impact of deviations to the established TMS treatment timing on treatment effectiveness.
  • Presentation Date: June 14th at 4:00 PM BST

Accelerated Transcranial Magnetic Stimulation: Preliminary Efficacy Findings Using a Pragmatic Tool

  • Presented by: Sonder Behavioral Health & Wellness, Minnetonka, Minnesota
  • Overview: This study will showcase feasibility, safety, and efficacy results using NeuroStar with a pragmatic accelerated TMS protocol without the need for neuroimaging.
  • Presentation Date: June 14th at 4:00 PM BST

Effectiveness of TMS for Adolescents and Young Adult Real World Outcomes in Patients with Major Depressive Disorder

  • Presenter: Dr. Paul E. Croarkin, Associate Professor of Psychiatry and Psychology, Division Chair, Child and Adolescent Psychiatry, Mayo Clinic College of Medicine and Science
  • Overview: Dr. Croarkin will discuss data that led to NeuroStar's latest FDA clearance to treat adolescents as a first-line, adjunct treatment for major depressive disorder (MDD).
  • Presentation Date: June 14th at 4:00 PM BST

Sensitivity of the PHQ-9 and QIDS-SR16 to the Therapeutic Effects of TMS in Major Depressive Disorder

  • Presenter: Dr. Kenneth Pages, Medical Director of TMS of South Tampa
  • Overview: Dr. Pages will contrast the Patient Health Questionnaire-9 (PHQ-9) and the Quick Inventory of Depressive Symptomatology (QIDS-SR16) regarding each scale’s sensitivity to detection of symptom changes in patients with MDD.
  • Presentation Date: June 14th at 4:00 PM BST

Symptom Profiles Before and After TMS in Major Depressive Disorder

  • Presenter: Dr. Todd Hutton, Chief Medical Director at Southern California TMS Center
  • Overview: Dr. Hutton will identify the impact of TMS on individual symptom domains of MDD utilizing both the PHQ-9 and QIDS-SR16.
  • Presentation Date: June 14th at 4:00 PM BST

For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.

About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.